(Q45141063)

10 December 2017

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status (English)

1 reference

10 December 2017

Gee-Chen Chang

1

1 reference

10 December 2017

Kun-Chieh Chen

2

1 reference

10 December 2017

Tsung-Ying Yang

3

1 reference

10 December 2017

Ming-Chang Yin

4

1 reference

10 December 2017

Ching-Pei Lin

5

1 reference

10 December 2017

Benjamin Ing-Tiau Kuo

6

1 reference

10 December 2017

Jeng-Yuan Hsu

7

1 reference

10 December 2017

1 January 2005

1 reference

Investigational New Drugs

10 December 2017

1 reference

10 December 2017

23

1 reference

10 December 2017

1

1 reference

10 December 2017

73-77

1 reference

https://scigraph.springernature.com/pub.10.1023/b:drug.0000047108.39129.7c

10 December 2017

0 references

cites work

Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.

1 reference

12 December 2020

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Management strategies for recurrent non-small cell lung cancer.

1 reference

12 December 2020

Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype

1 reference

12 December 2020

Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer

1 reference

12 December 2020

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

1 reference

12 December 2020

Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer

1 reference

12 December 2020

10.1023/B:DRUG.0000047108.39129.7C

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

0 references

1 reference